Burns patients require antimicrobial therapy for burn wound cellulitis in 16.3% of admissions.

There is presently little data to describe how effectively first line antimicrobials like flucloxacillin and lincomycin penetrate into the site of infection in the burn wound. In this study, we will use the in vivo sampling technique microdialysis to determine antimicrobial concentrations in burn wound tissue.

This pharmacokinetic data can then be used to develop optimised dosing that ensures therapeutic concentrations at the site of infection which may help prevent the frequently observed prolonged courses of therapy that are used and sometimes eventuate in treatment failure.

Project members

Professor Jason Roberts

Chief Investigator and CRE lead

Professor Jeffrey Lipman

Chief Investigator